CSL Ltd (ASX:CSL)
A$ 283.99 -2.35 (-0.82%) Market Cap: 137.51 Bil Enterprise Value: 153.48 Bil PE Ratio: 35.09 PB Ratio: 5.29 GF Score: 97/100

CSL Ltd Research and Development Investor Briefing Transcript

Nov 02, 2022 / 10:00PM GMT
Release Date Price: A$282.71 (-0.19%)
Mark Dehring
CSL Limited - Head of IR

Ladies and gentlemen, good morning, and welcome to CSL's Annual Research & Development Briefing. It's Mark Dehring speaking. And online with me today is Dr. Bill Mezzanotte, Executive Vice President, Head of Research & Development and Chief Medical Officer. He is joined by several of his senior team. Also, joining us once again is Bill Campbell, Executive Vice President and Chief Commercial Officer, CSL Behring. Bill will be providing us with some market insights on CSL Behring's product portfolio.

Please be aware this presentation as well as the Q&A session is being webcast. And lastly, before we start, I draw your attention to the forward statement disclaimer within the slide deck. I'll now hand you over to Bill Mezzanotte. Bill?

William Mezzanotte
CSL Limited - Executive VP, Head of Research & Development and Chief Medical Officer

Mark, and welcome to all who are joining for the 2022 virtual R&D update. I'm really excited to be hosting today. This is my sixth R&D presentation, fourth

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot